FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Williams Timothy					2. Issuer Name and Ticker or Trading Symbol Vanda Pharmaceuticals Inc. [VNDA]								(Check	all applicable) Director		10% (Owner
(Last) (First) (Middle) C/O VANDA PHARMACEUTICALS INC. 2200 PENNSYLVANIA AVENUE, SUITE 300E					3. Date of Earliest Transaction (Month/Day/Year) 03/02/2020								X	below) below) SVP & General Counsel			
(Street) WASHINGTON DC 20037 (City) (State) (Zip)					4. If Amendment, Date of Original Filed (Month/Day/Year)								vidual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person				
	Tabl	e I - 1	Non-Deriv	ative	Seci	uritie	s Ac	quire	ed, Di	sposed o	f, or E	Benefic	ially (Owne	ed		
Date					Execution Date,		3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Oisposed Of (D) (Instr. 3, 4 and Code (Instr. 3) or Oisposed Of (D) (Instr. 3) or Oisposed Of (nd 5) Se Be Ov		ities icially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership		
								Code	v	Amount	(A) or (D)	Price		Trans	action(s)		(Instr. 4)
Common Stock 03/02/202					20			S ⁽¹⁾		3,148	D	\$10.30	10.3036(2)		34,277	D	
Common Stock 03/03/202					20			S ⁽¹⁾		1,237	D	\$10.5	\$10.5124		33,040	D	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
Derivative Conversion Date Ex Security or Exercise (Month/Day/Year) if a					Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		ation D	ate Year)	Amour or Numbe of		Deriv Secu	ivative urity	derivative Securities Beneficially Owned Following Reported	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
	(Fir IDA PHAR NNSYLVAN (Statement of Stock) Stock Stock 2. Conversion or Exercise Price of Derivative	(First) (IDA PHARMACEUTICAL NNSYLVANIA AVENUE, S IGTON DC 2 (State) (I Tabl Security (Instr. 3) Stock Stock Ta 2. Conversion or Exercise Price of Date (Month/Day/Year) Privative (Month/Day/Year)	(First) (Middle IDA PHARMACEUTICALS INCONSYLVANIA AVENUE, SUITE IGTON DC 20037 (State) (Zip) Table I - I Gecurity (Instr. 3) Stock Table II 2. Conversion or Exercise Price of Derivative Idan (Month/Day/Year) In any (Month Idan) In any (Month Idan) Idan (Month	(First) (Middle) IDA PHARMACEUTICALS INC. NNSYLVANIA AVENUE, SUITE 300E IGTON DC 20037 (State) (Zip) Table I - Non-Derivate (Month/Day/Stock) Stock 03/02/20 Table II - Derivate (e.g., propriete of Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 2. Table II - Derivate (e.g., propriete of Date (Month/Day/Year)	IS Timothy. (First) (Middle) 3. Date (Middle) 3. Date (Month/Day/Year) Stock 3. Transaction Date (Month/Day/Year) 2. Conversion or Exercise Price of Perivative (Month/Day/Year) (State) 3. Transaction Date (Month/Day/Year) 3. Deemed Execution Date, if any (Month/Day/Year) (Month/Day/Year) 4. Transactor (Month/Day/Year) 3. Deemed Execution Date, if any (Month/Day/Year) (Month/Day/Year) 4. Transactor (Month/Day/Year)	(First) (Middle) IDA PHARMACEUTICALS INC. NNSYLVANIA AVENUE, SUITE 300E IGTON DC 20037 (State) (Zip) Table I - Non-Derivative Security (Instr. 3) 2. Transaction Date (Month/Day/Year) Stock 1. Table II - Derivative Security (e.g., puts, calls, if any (Month/Day/Year) 2. Table II - Derivative Security (e.g., puts, calls, if any (Month/Day/Year) 2. Table II - Derivative Security (e.g., puts, calls, if any (Month/Day/Year) 3. Date of 03/02/2020 4. If Amend 203/02/2020 2. Table II - Derivative Security (e.g., puts, calls, if any (Month/Day/Year) 3. Date of 03/02/2020 4. If Amend 203/02/2020 2. Table II - Derivative Security (e.g., puts, calls, if any (Month/Day/Year) 3. Date of 03/02/2020 4. If Amend 203/02/2020 2. Transaction Date (if any (Month/Day/Year)) 3. Transaction Date (if any (Month/Day/Year))	Vanda Pharias Timothy. (First) (Middle) IDA PHARMACEUTICALS INC. NNSYLVANIA AVENUE, SUITE 300E (State) (Zip) Table I - Non-Derivative Securities (Month/Day/Year) Stock Stock 03/02/2020 Table II - Derivative Securities (e.g., puts, calls, warr (Month/Day/Year) 2. Table II - Derivative Securities (e.g., puts, calls, warr (Month/Day/Year) 2. Table II - Derivative Securities (e.g., puts, calls, warr (Month/Day/Year) 3. Date of Earlies 03/02/2020 4. If Amendment, 2A. Deemed Execution Date (Imprise of Code (Instr. 8) 4. Transaction Code (Instr. 8) 5. Nu Transaction Of Code (Instr. 8) 6. Output Date (Month/Day/Year) 7. Output Date (Imprise of Code (Instr. 8) 8. Output Date (Imprise of Code (Instr. 8) 8. Output Date (Imprise of Code (Instr. 8) 9. Output Date	(First) (Middle) JDA PHARMACEUTICALS INC. NNSYLVANIA AVENUE, SUITE 300E Table I - Non-Derivative Securities Acquired (e.g., puts, calls, warrants 2. Transaction Date (Instr. 3) Table II - Derivative Securities Acquired (e.g., puts, calls, warrants 2. Transaction Date (e.g., puts, calls, warrants) A Deemed Execution Date, if any (Month/Day/Year) Table II - Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) A Deemed Execution Date, if any (Month/Day/Year) A Conversion Or Exercise Price of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	Vanda Pharmaceutic Vanda Pharmaceutic 3. Date of Earliest Transaction 03/02/2020 4. If Amendment, Date of Orig Table I - Non-Derivative Securities Acquired (Month/Day/Year) Force of Derivative Securities Acquired (e.g., puts, calls, warrants, option of Conversion or Exercise Price of Derivative Security 2. Transaction Date (Month/Day/Year) 3. Date of Earliest Transaction 03/02/2020 4. If Amendment, Date of Orig 2. Transaction Date (Month/Day/Year) (Month/Day/Year) 3. Transaction Date (e.g., puts, calls, warrants, option of Code (Instr. 8) 3. Transaction Transaction Date (Month/Day/Year) 3. Transaction Date (e.g., puts, calls, warrants, option of Code (Instr. 8) 4. Transaction Transaction Date (Month/Day/Year) 5. Number of Original Pharmaceutic (Instr. 100 (Month/Day/Year)) 4. Transaction Transaction Date (Instr. 8) 5. Number of Original Pharmaceutic (Instr. 8) 6. Date Date (Instr. 3)	Vanda Pharmaceuticals In Vanda Pharmaceutic	(First) (Middle) (IDA PHARMACEUTICALS INC. NNSYLVANIA AVENUE, SUITE 300E Table I - Non-Derivative Securities Acquired, Disposed of (Month/Day/Year) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of (Month/Day/Year) (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) (Month/Day/Year) 2B. Code (Instr. 8) Table II - Derivative Securities Acquired, Disposed of (e.g., puts, calls, warrants, options, convertib 2. Table II - Derivative Securities Acquired, Disposed of (e.g., puts, calls, warrants, options, convertib acquired (A) or (Month/Day/Year) (Month/Day/Year) Stock 3. Transaction Date (e.g., puts, calls, warrants, options, convertib acquired (A) or (Month/Day/Year) (Month/Day/Year) Stock 3. Transaction Date (e.g., puts, calls, warrants, options, convertib acquired (A) or (Month/Day/Year) (Month/Day/Year) Stock 5. No. Table II - Derivative Securities Acquired (A) or (B. Date Exercisable and Expiration Date (A) or (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) Stock 5. No. Table II - Derivative Securities Acquired (A) or (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year)	Vanda Pharmaceuticals Inc. [VNDA] Vanda Pharmaceuticals Inc. [VNDA] 3. Date of Earliest Transaction (Month/Day/Year) 03/02/2020 4. If Amendment, Date of Original Filed (Month/Day/Year) o3/02/2020 Table I - Non-Derivative Securities Acquired, Disposed of, or Exercision Date (Month/Day/Year) o2/2020 Table II - Derivative Securities Acquired, Disposed of (D) (Instr. 3) Table II - Derivative Securities Acquired, Disposed of (D) (Instr. 3) Table II - Derivative Securities Acquired, Disposed of (D) (Instr. 3) Table II - Derivative Securities Acquired, Disposed of (D) (Instr. 3) Table II - Derivative Securities Acquired, Disposed of, or Bel (e.g., puts, calls, warrants, options, convertible Securities Acquired (A) or Derivative Securities Acquired (A) or Derivative Securities Acquired (Month/Day/Year) (Mo	Vanda Pharmaceuticals Inc. VNDA	Vanda Pharmaceuticals Inc. (VNDA Check X Vanda Pharmaceuticals Inc. (VNDA Check X Vanda Pharmaceuticals Inc. (VNDA X Vanda Pharmaceuticals Inc. (VNDA Year) (VNDA Pharmaceuticals Inc. (VNDA Pharmaceutic	Vanda Pharmaceuticals Inc. [VNDA] (First) (Middle) (Midd	Vanda Pharmaceuticals Inc. VNDA Check all applicable Director Director Officer (give title below) SVP & Gen	Vanda Pharmaceuticals Inc. VNDA Check all applicable) Vanda Pharmaceuticals Inc. VNDA Check all applicable) Vanda Pharmaceuticals Inc. VNDA VNDA V

Explanation of Responses:

- 1. Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$10.30 to \$10.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

Remarks:

/s/ Timothy Williams 03/03/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.